RBO & Co’s GSK GSK Stock Holding History

RBO & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-4,366	Closed	-$220K	–	65
2018 Q2	$220K	Hold	4,366	–	–	0.06%	66
2018 Q1	$213K	Buy	+4,366	New	+$203K	0.05%	51

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

RBO & Co's GSK Position: Q3 2018 in Review

RBO & Co sold out of GSK (GSK) in Q3 2018, closing a stake of 4,366 shares — an estimated $220K sold.

RBO & Co first reported a position in GSK in Q1 2018 and held it in 2 quarters. The position peaked at $220K in Q2 2018. 787 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

RBO & Co reported no remaining GSK position as of Q3 2018 after selling out during the quarter.
RBO & Co sold 4,366 GSK shares in Q3 2018, an estimated $220K.
RBO & Co first reported a position in GSK in Q1 2018 and held it in 2 quarters.
RBO & Co's GSK position peaked at $220K in Q2 2018.
787 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on RBO & Co's 13F filing for Q3 2018, filed 14 Nov 2018.